PL3718565T3 - Szczepionki przeciwko wirusom układu oddechowego - Google Patents

Szczepionki przeciwko wirusom układu oddechowego

Info

Publication number
PL3718565T3
PL3718565T3 PL20164728.6T PL20164728T PL3718565T3 PL 3718565 T3 PL3718565 T3 PL 3718565T3 PL 20164728 T PL20164728 T PL 20164728T PL 3718565 T3 PL3718565 T3 PL 3718565T3
Authority
PL
Poland
Prior art keywords
virus vaccines
respiratory virus
respiratory
vaccines
virus
Prior art date
Application number
PL20164728.6T
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Sunny HIMANSU
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58558175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3718565(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of PL3718565T3 publication Critical patent/PL3718565T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL20164728.6T 2015-10-22 2016-10-21 Szczepionki przeciwko wirusom układu oddechowego PL3718565T3 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562244802P 2015-10-22 2015-10-22
US201562245031P 2015-10-22 2015-10-22
US201562244837P 2015-10-22 2015-10-22
US201562244813P 2015-10-22 2015-10-22
US201562244946P 2015-10-22 2015-10-22
US201562247394P 2015-10-28 2015-10-28
US201562247483P 2015-10-28 2015-10-28
US201562247362P 2015-10-28 2015-10-28
US201562247297P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
PL3718565T3 true PL3718565T3 (pl) 2022-09-19

Family

ID=58558175

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20164728.6T PL3718565T3 (pl) 2015-10-22 2016-10-21 Szczepionki przeciwko wirusom układu oddechowego

Country Status (16)

Country Link
US (7) US10064934B2 (pl)
EP (5) EP4349404A2 (pl)
DE (1) DE20164728T1 (pl)
DK (1) DK3718565T3 (pl)
ES (1) ES2922760T3 (pl)
HR (1) HRP20220872T1 (pl)
HU (1) HUE059127T2 (pl)
LT (1) LT3718565T (pl)
MA (2) MA47016A (pl)
MD (1) MD3718565T2 (pl)
PL (1) PL3718565T3 (pl)
PT (1) PT3718565T (pl)
RS (1) RS63381B1 (pl)
SI (1) SI3718565T1 (pl)
TW (1) TW201729835A (pl)
WO (1) WO2017070626A2 (pl)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013120499A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
RU2746406C2 (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
HRP20220872T1 (hr) 2015-10-22 2022-12-23 Modernatx, Inc. Cjepiva protiv respiratornih virusa
PE20181529A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacunas de acido nucleico para el virus varicela-zoster (vzv)
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
MD3386484T2 (ro) 2015-12-10 2022-11-30 Modernatx Inc Compoziții și metode de livrare a unor agenți terapeutici
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
US10799573B2 (en) * 2016-03-30 2020-10-13 Regents Of The University Of Minnesota Pertussis vaccines and methods of making and using
BR112018073683A2 (pt) 2016-05-18 2019-02-26 Modernatx, Inc. polinucleotídeos codificadores de relaxina
MX2019002904A (es) 2016-09-14 2019-09-26 Modernatx Inc Composiciones de arn de alta pureza y métodos para su preparación.
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3551193A4 (en) * 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
WO2018170260A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11045540B2 (en) * 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
WO2018170347A1 (en) * 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018232355A1 (en) * 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20200254086A1 (en) * 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
JP7408098B2 (ja) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) * 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
JP7424976B2 (ja) * 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN112399860A (zh) 2018-06-06 2021-02-23 麻省理工学院 用于在真核细胞中翻译的环状rna
CN112805294A (zh) 2018-09-28 2021-05-14 胡桃钳医疗公司 用于核酸递送的叔氨基脂化的阳离子肽
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CA3130888A1 (en) 2019-02-20 2020-08-27 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CA3134944A1 (en) * 2019-03-25 2020-10-01 Ohio State Innovation Foundation Engineered mrna sequences and uses thereof
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
WO2021055833A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4289951A3 (en) * 2019-12-04 2024-03-13 Orna Therapeutics, Inc. Circular rna compositions and methods
CN115515628A (zh) 2019-12-11 2022-12-23 美国政府(由卫生和人类服务部的部长所代表) 腮腺炎和麻疹病毒免疫原及其用途
KR20220133224A (ko) * 2020-01-28 2022-10-04 모더나티엑스, 인크. 코로나바이러스 rna 백신
MX2022009429A (es) * 2020-01-30 2022-08-25 Modernatx Inc Composiciones para la inmunizacion contra virus respiratorios.
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
CA3167257A1 (en) * 2020-02-07 2021-08-12 Shenggao TANG Composition and method of mrna vaccines against novel coronavirus infection
IL295377A (en) 2020-02-07 2022-10-01 Modernatx Inc sars-cov-2 mRNA domain vaccines
WO2021188906A1 (en) * 2020-03-19 2021-09-23 Nature's Toolbox, Inc. Novel mrna-based covid-19 multi-valent vaccine and methods of scaled production of the same
WO2021202923A1 (en) 2020-04-02 2021-10-07 Nektar Therapeutics Immunomodulator for the prevention and treatment of coronovirus infection and other conditions
RU2747762C1 (ru) * 2020-04-05 2021-05-13 Илья Владимирович Духовлинов Вакцина для профилактики или лечения коронавирусной инфекции на основе генетической конструкции
FI20205382A1 (en) * 2020-04-09 2021-05-07 Niemelae Erik Method for preventing the spread of pathogens and for reducing infections caused by them
CN113874507A (zh) * 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
MX2022013254A (es) 2020-04-22 2023-01-24 BioNTech SE Vacuna contra el coronavirus.
WO2021222304A1 (en) * 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
US20230181681A1 (en) * 2020-05-08 2023-06-15 Industry Academic Cooperation Foundation, Hallym University Peptide for suppressing coronavirus and use thereof
US20230226170A1 (en) * 2020-05-12 2023-07-20 Greffex, Inc. Engineering coronavirus spike proteins as vaccine antigens, their design and uses
WO2021159130A2 (en) * 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
EP4153224A1 (en) * 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Coronavirus antigen compositions and their uses
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
EP4175982A1 (en) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
WO2022011021A1 (en) * 2020-07-07 2022-01-13 Ascendo Biotechnology, Inc. Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine
US20230248818A1 (en) * 2020-07-08 2023-08-10 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2
EP4179112A2 (en) 2020-07-13 2023-05-17 The Board of Trustees of the Leland Stanford Junior University Systems and methods to assess rna stability
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022047427A2 (en) 2020-08-31 2022-03-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for producing rna constructs with increased translation and stability
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
WO2022067010A1 (en) 2020-09-25 2022-03-31 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
WO2022135993A2 (en) * 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) * 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
KR20230135586A (ko) 2021-01-24 2023-09-25 마이클 데이비드 포레스트 Atp 합성효소 억제제 - 미용 및 치료 용도
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2022237382A1 (en) 2021-03-15 2023-09-28 Modernatx, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
JP2024514182A (ja) * 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド 呼吸器ウイルス組み合わせワクチン
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
WO2022241415A1 (en) * 2021-05-11 2022-11-17 Yale University Methods for monoclonal antibody generation
TW202248421A (zh) * 2021-06-11 2022-12-16 亞諾法生技股份有限公司 信使核糖核酸疫苗與在個體中誘發抗原特異性免疫反應之方法
CN113249408B (zh) * 2021-06-23 2021-11-02 深圳湾实验室 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
WO2023275538A1 (en) 2021-06-28 2023-01-05 Diosynvax Ltd Beta-coronavirus vaccines
WO2023273364A1 (zh) 2021-06-30 2023-01-05 天津键凯科技有限公司 聚乙二醇脂质及其应用
CN114149337B (zh) 2021-07-07 2022-04-29 天津键凯科技有限公司 一种用于核酸递送的新型可电离脂质及其lnp组合物
WO2023019181A1 (en) * 2021-08-11 2023-02-16 Modernatx, Inc. Sars-cov-2 lipid nanoparticle vaccine formulations
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023044346A2 (en) 2021-09-14 2023-03-23 Ausper Biopharma Co., Ltd. Vaccines for coronavirus prevention and treatment
AU2022360009A1 (en) 2021-10-06 2024-05-23 Diosynvax Ltd Influenza vaccines
CA3234656A1 (en) 2021-10-06 2023-04-13 Diosynvax Ltd Coronavirus vaccines
WO2023067560A1 (en) * 2021-10-22 2023-04-27 Seqirus Inc. Ionizable cationic compound
CA3235867A1 (en) 2021-10-22 2023-04-27 Munir MOSAHEB Mrna vaccine composition
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023079507A1 (en) * 2021-11-05 2023-05-11 Sanofi Respiratory syncytial virus rna vaccine
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2023086961A1 (en) 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
WO2023094885A2 (en) 2021-11-29 2023-06-01 Arabian Gulf University Antigenic determinants, protective immunity, serodiagnostic and multivalent subunits precision vaccine against sars-cov-2
US20230338512A1 (en) * 2021-11-29 2023-10-26 BioNTech SE Coronavirus vaccine
IT202100030398A1 (it) 2021-12-01 2023-06-01 Pomona Ricerca Srl Minibody come vaccini per l’hiv
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
WO2023110422A1 (en) 2021-12-16 2023-06-22 Stefan Grabuschnig Vaccine preparation
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
KR102465349B1 (ko) 2022-02-25 2022-11-11 주식회사 테르나테라퓨틱스 신규 이온화 지질 및 이를 포함하는 지질 나노입자
WO2023178182A1 (en) 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (402)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
CA1335429C (en) 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
EP0413695B1 (en) 1988-04-22 1994-05-04 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3.
EP0465529B1 (en) 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
EP0625049A4 (en) 1992-01-23 1995-07-12 Vical Inc EX VIVO GENTRANSFER.
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995033835A1 (en) 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US7208161B1 (en) 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
CA2305785A1 (en) 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
WO1999033982A2 (en) 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
AU7725500A (en) 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
EP1604688B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
CA2462593A1 (en) 2001-10-03 2003-04-10 Kam W. Leong Compositions for oral gene therapy and methods of using same
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
MXPA04008088A (es) 2002-02-21 2005-09-30 Medimmune Vaccines Inc Sistema de expresion del virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metapneumovirus.
WO2003092665A2 (en) 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
DE10221836A1 (de) 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
KR101187955B1 (ko) 2003-04-25 2012-10-08 비로노바티브 비브이 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합파라인플루엔자 바이러스 발현 시스템 및 백신
EP2494986A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
WO2005027963A2 (en) * 2003-09-15 2005-03-31 The United States Of America As Represented By Thesecretary Of Health And Human Services, Nih METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CN101084016A (zh) 2004-04-15 2007-12-05 克艾思马有限公司 能够容易穿透生物学障碍的组合物
EP1751178A2 (en) 2004-06-04 2007-02-14 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
WO2006056027A1 (en) 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
US8354476B2 (en) 2004-12-10 2013-01-15 Kala Pharmaceuticals, Inc. Functionalized poly(ether-anhydride) block copolymers
WO2006071903A2 (en) 2004-12-28 2006-07-06 Ptc Therapeutics, Inc. Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP2290363B1 (en) 2005-03-11 2014-01-08 Firalis SAS Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
KR101288729B1 (ko) 2005-04-01 2013-07-23 인터자인 테크놀로지스, 인코포레이티드 약물 전달용 중합체성 마이셀
WO2006110214A2 (en) 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
EP2279758B1 (en) 2005-06-16 2015-02-25 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
ES2735531T3 (es) 2005-08-23 2019-12-19 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
WO2007038862A1 (en) * 2005-10-03 2007-04-12 Seneca College Of Applied Arts & Technology Nucleic acid immunological composition for human metapneumovirus
EP2026839A4 (en) 2005-12-14 2009-04-01 Univ Oklahoma RNA VIRUS VACCINE AND METHODS
DE102006007433A1 (de) 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
CN103030801B (zh) 2006-02-21 2015-07-22 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
CN101415405A (zh) 2006-04-04 2009-04-22 Stc.Unm公司 用于药物递送的可溶胀颗粒
FR2899902B1 (fr) 2006-04-18 2012-01-27 Agronomique Inst Nat Rech Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet et leurs utilisations pour la vaccination et la vectorisation intra-cellulaire.
CN101573141B (zh) 2006-05-15 2016-05-04 麻省理工学院 用于功能性颗粒的聚合物
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
US20100215580A1 (en) 2006-09-08 2010-08-26 The Johns Hopkins University Compositions and methods for enhancing transport through mucus
US20110135645A1 (en) 2006-10-04 2011-06-09 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
MX2009003680A (es) 2006-10-05 2009-07-17 Univ Johns Hopkins Formulaciones orales, parenterales y topicas dispersables en agua para farmacos deficientemente solubles en agua con el uso de nanoparticulas polimericas inteligentes.
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
EP2120859B1 (en) 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
US20090162395A1 (en) 2007-09-26 2009-06-25 Crowe Jr James E Vaccine for rsv and mpv
HUE034775T2 (hu) 2007-09-28 2018-02-28 Pfizer Rákos sejt célzása nanorészecskék alkalmazásával
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
KR101483715B1 (ko) 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CA2984026C (en) 2008-10-09 2020-02-11 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
AU2015210364B2 (en) 2008-10-09 2017-03-09 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
MX359674B (es) 2008-11-10 2018-10-05 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
KR20120022984A (ko) 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
US8460680B2 (en) * 2009-04-24 2013-06-11 National Health Research Institutes Polyvalent chimeric rubella virus-based vaccines
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
JP5769701B2 (ja) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 脂質組成物
CN102481376B (zh) 2009-05-27 2016-12-21 西莱克塔生物科技公司 免疫调节剂-聚合物化合物
KR102205886B1 (ko) 2009-06-10 2021-01-21 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US9937196B2 (en) 2009-06-19 2018-04-10 University Of Maryland, College Park Genomic sequence of avian paramyxovirus type 2 and uses thereof
AU2010264686A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
RU2573409C2 (ru) 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
US8449916B1 (en) 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
GB0920304D0 (en) 2009-11-20 2010-01-06 Medical Res Council Novel liposome nanoparticles for tumour magnetic resonance imaging
TR201901311T4 (tr) 2009-12-01 2019-02-21 Translate Bio Inc İnsan genetik hastalıklarında mRNA'nın teslimi için steroid türevi.
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
WO2011084518A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
WO2012082165A1 (en) 2010-01-24 2012-06-21 Novartis Ag Irradiated biodegradable polymer microparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
WO2011150320A2 (en) 2010-05-27 2011-12-01 University Of Georgia Research Foundation, Inc. Activators of innate immunity
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
BRPI1001959A2 (pt) 2010-06-15 2012-03-06 Instituto De Pesquisas Tecnológicas Do Est. S. Paulo S/a - Ipt Nanocarreadores coloidais para ativos hidrofílicos e processo de produção
WO2011163483A2 (en) 2010-06-25 2011-12-29 Massachusetts Institute Of Technology Polymers for biomaterials and therapeutics
KR101130137B1 (ko) 2010-07-02 2012-03-28 연세대학교 산학협력단 발광다이오드 모듈
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PL3243526T3 (pl) 2010-07-06 2020-05-18 Glaxosmithkline Biologicals S.A. Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
US10487332B2 (en) * 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
EP2955230A1 (en) 2010-07-30 2015-12-16 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012021516A2 (en) 2010-08-09 2012-02-16 The Trustees Of The University Of Pennsylvania Nanoparticle-oligonucletide hybrid structures and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US8956646B2 (en) 2010-08-14 2015-02-17 The Regents Of The University Of California Zwitterionic lipids
AU2011291522A1 (en) 2010-08-20 2013-01-24 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E
DK3981427T3 (da) * 2010-08-31 2022-07-11 Glaxosmithkline Biologicals Sa Pegylerede liposomer til afgivelse af immunogen-kodende RNA
ES2727583T3 (es) 2010-08-31 2019-10-17 Glaxosmithkline Biologicals Sa Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
FI4043040T3 (fi) 2010-08-31 2023-04-04 Glaxosmithkline Biologicals Sa Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
US20120177701A1 (en) 2010-12-31 2012-07-12 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods
DK3202760T3 (da) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
JP2014505477A (ja) 2011-01-28 2014-03-06 メディミューン，エルエルシー 哺乳類細胞中の可溶性ウイルス融合糖タンパク質の発現
US20140066363A1 (en) 2011-02-07 2014-03-06 Arun K. Bhunia Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
AU2012237260A1 (en) 2011-03-31 2013-11-14 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
EP2691078A1 (en) 2011-03-31 2014-02-05 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
AU2012255913A1 (en) 2011-05-17 2013-11-21 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
ES2685333T3 (es) 2011-06-02 2018-10-08 The Regents Of The University Of California Nanopartículas encapsuladas en membrana y método de utilización
US8916696B2 (en) 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
JP6018197B2 (ja) 2011-07-21 2016-11-02 クローダ インターナショナル パブリック リミティド カンパニー 分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
JP2014527071A (ja) 2011-08-31 2014-10-09 マリンクロッド エルエルシー Ｈ−ホスホネートによるナノ粒子ｐｅｇの改変
TR201900264T4 (tr) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
JP2014531456A (ja) 2011-09-22 2014-11-27 バインド セラピューティックス インコーポレイテッド 治療用ナノ粒子と癌を治療する方法
WO2013072929A2 (en) 2011-09-23 2013-05-23 Indian Institute Of Technology Nanop article based cosmetic composition
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
WO2013055905A1 (en) 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
MX2014004415A (es) 2011-10-14 2015-06-05 Stc Unm Bicapas lipidicas soportadas por nanoparticulas porosas (protecelulas) para suministro dirigido, incluido el suministro transdermico de carga, y los metodos relacionados.
ES2745373T3 (es) 2011-10-18 2020-03-02 Dicerna Pharmaceuticals Inc Lípidos catiónicos de amina y uso de los mismos
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
CA3119789A1 (en) 2011-10-27 2013-05-02 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
CA2851828A1 (en) 2011-10-28 2013-05-02 Presage Biosciences, Inc. Methods for drug delivery
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
EP2785326A2 (en) 2011-11-29 2014-10-08 The University of North Carolina at Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP2791159A4 (en) 2011-12-14 2015-10-14 Moderna Therapeutics Inc MODIFIED NUCLEIC ACIDS, AND SHORT-TERM CARE USES THEREOF
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
MX2014007233A (es) * 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
WO2013090601A2 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Compact nanoparticles for biological applications
CN104968354A (zh) 2011-12-21 2015-10-07 现代治疗公司 增加器官或器官外植体的活力或寿命的方法
EP4372081A2 (en) 2011-12-30 2024-05-22 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
WO2013105101A1 (en) 2012-01-13 2013-07-18 Department Of Biotechnology Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
CN104936620B (zh) 2012-01-19 2019-08-09 约翰霍普金斯大学 增强粘膜渗透的纳米粒子调配物
EP3312155B1 (en) 2012-02-03 2020-08-05 Rutgers, The State University of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
KR102019297B1 (ko) 2012-02-09 2019-09-06 라이프 테크놀로지스 코포레이션 친수성 중합체성 입자 및 그의 제조 방법
US20150337068A1 (en) 2012-02-10 2015-11-26 Karl K Berggren Preparation, purification and use of high-x diblock copolymers
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
CN104394853B (zh) 2012-02-19 2017-10-10 纳维基因股份有限公司 多孔性纳米结构在递送中的用途
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
AU2013237874B2 (en) 2012-03-29 2018-01-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2858679B1 (en) * 2012-06-08 2021-02-24 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
CA2873274C (en) 2012-06-08 2021-06-01 Ethris Gmbh Pulmonary delivery of messenger rna
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US20150366997A1 (en) * 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
CA2891911C (en) 2012-12-07 2023-03-07 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
WO2014093574A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
MX2015011955A (es) 2013-03-08 2016-04-07 Novartis Ag Lipidos y composiciones de lipidos para el suministro de agentes activos.
KR20220139415A (ko) 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
ES2692363T3 (es) 2013-03-14 2018-12-03 Translate Bio, Inc. Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
SI2970456T1 (sl) * 2013-03-14 2022-01-31 Translate Bio, Inc. Postopki in sestavki za dostavo MRNA-kodiranih protiteles
ES2670529T3 (es) * 2013-03-15 2018-05-30 Translate Bio, Inc. Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
WO2014172045A1 (en) 2013-03-15 2014-10-23 The University Of British Columbia Lipid nanoparticles for transfection and related methods
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
WO2014144153A2 (en) 2013-03-15 2014-09-18 Ohio State Innovation Foundation Metapneumovirus immunogens and related materials and methods
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
JP7019233B2 (ja) 2013-07-11 2022-02-15 モデルナティエックス インコーポレイテッド ＣＲＩＳＰＲ関連タンパク質をコードする合成ポリヌクレオチドおよび合成ｓｇＲＮＡを含む組成物ならびに使用方法
CN105473157A (zh) 2013-08-21 2016-04-06 库瑞瓦格股份公司 组合疫苗
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
JP6412131B2 (ja) 2013-11-29 2018-10-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＥＲＳ‐ＣｏＶワクチン
EP3083556B1 (en) * 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
DK3090053T3 (en) 2013-12-30 2019-02-25 Curevac Ag Artificial nucleic acid molecules
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
WO2015130584A2 (en) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015143335A1 (en) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
RU2746406C2 (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016011306A2 (en) 2014-07-17 2016-01-21 Moderna Therapeutics, Inc. Terminal modifications of polynucleotides
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
CA2975853A1 (en) 2015-02-08 2016-08-11 Tongli Biomedical Co., Ltd. Lipid nanoparticles and uses thereof
EP3261665A1 (en) 2015-02-24 2018-01-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EP3307305A4 (en) 2015-06-10 2019-05-22 Modernatx, Inc. TARGETED ADAPTIVE VACCINES
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2017019935A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Multimeric mrna
US20190008938A1 (en) 2015-07-30 2019-01-10 Modernatx, Inc. Concatemeric peptide epitope rnas
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
US11311615B2 (en) 2015-09-16 2022-04-26 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
HRP20220872T1 (hr) 2015-10-22 2022-12-23 Modernatx, Inc. Cjepiva protiv respiratornih virusa
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
CA3003090A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
PE20181529A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacunas de acido nucleico para el virus varicela-zoster (vzv)
WO2017070620A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
US20180303929A1 (en) 2015-10-22 2018-10-25 Moderna TX, Inc. Herpes simplex virus vaccine
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
BR112018008102A2 (pt) 2015-10-22 2018-11-06 Modernatx Inc vacina de vírus sincicial respiratório
CA3003267A1 (en) 2015-10-26 2017-05-04 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017081082A2 (en) 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
MD3386484T2 (ro) 2015-12-10 2022-11-30 Modernatx Inc Compoziții și metode de livrare a unor agenți terapeutici
EP3390630A1 (en) 2015-12-17 2018-10-24 Modernatx, Inc. POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
MX2018012095A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
US11001861B2 (en) 2016-05-18 2021-05-11 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
US20200085916A1 (en) 2016-05-18 2020-03-19 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
US20190390181A1 (en) 2016-05-18 2019-12-26 Modernatx, Inc. Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia
AU2017268396B2 (en) 2016-05-18 2023-05-18 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
BR112018073683A2 (pt) 2016-05-18 2019-02-26 Modernatx, Inc. polinucleotídeos codificadores de relaxina
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE
JP7246930B2 (ja) 2016-05-18 2023-03-28 モデルナティエックス インコーポレイテッド インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017286980B2 (en) 2016-06-30 2023-10-26 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
MX2019002904A (es) 2016-09-14 2019-09-26 Modernatx Inc Composiciones de arn de alta pureza y métodos para su preparación.
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
JP7289265B2 (ja) 2016-10-26 2023-06-09 キュアバック エスイー 脂質ナノ粒子ｍＲＮＡワクチン
JP2019532657A (ja) 2016-10-26 2019-11-14 モデルナティーエックス， インコーポレイテッド 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法
MA46643A (fr) 2016-10-26 2019-09-04 Modernatx Inc Méthodes et compositions pour le mappage d'arn
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
EP3577221A4 (en) 2017-02-01 2020-12-23 ModernaTX, Inc. SECONDARY POLYNUCLEOTIDE STRUCTURE
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
NZ755780A (en) 2017-02-01 2023-10-27 Modernatx Inc Rna cancer vaccines
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
SG11201907916TA (en) 2017-03-15 2019-09-27 Modernatx Inc Compounds and compositions for intracellular delivery of therapeutic agents
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018200737A1 (en) 2017-04-26 2018-11-01 Modernatx, Inc. Herpes simplex virus vaccine
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
JP7408098B2 (ja) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
BR112020008404A2 (pt) 2017-10-31 2020-11-03 Modernatx, Inc. nanopartículas lipídicas para a entrega de rna modificado codificando um polipeptídeo vegf-a
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
AU2018372922A1 (en) 2017-11-21 2020-06-11 Modernatx, Inc. Epstein-Barr virus vaccines
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
US20210268086A1 (en) 2018-06-27 2021-09-02 Modernatx, Inc. Personalized cancer vaccine epitope selection
AU2019338557A1 (en) 2018-09-13 2021-03-25 Modernatx, Inc. Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
JP2022501359A (ja) 2018-09-19 2022-01-06 モデルナティーエックス， インコーポレイテッド Ｐｅｇ脂質及びそれらの使用
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
JP2022501367A (ja) 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
JP2022506839A (ja) 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド Ｒｎａがんワクチン
AU2020214843A1 (en) 2019-01-31 2021-08-19 Modernatx, Inc. Methods of preparing lipid nanoparticles
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CA3130888A1 (en) 2019-02-20 2020-08-27 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
BR112021018526A2 (pt) 2019-03-19 2021-11-23 Arcturus Therapeutics Inc Método de fabricação de nanopartículas de rna encapsuladas em lipídio
US20220236253A1 (en) 2019-05-31 2022-07-28 Modernatx, Inc. Expanded t cell assay
US20220348900A1 (en) 2019-08-14 2022-11-03 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription
JP2022547313A (ja) 2019-09-11 2022-11-11 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
EP4031666A4 (en) 2019-09-19 2023-11-15 ModernaTX, Inc. CAP GUIDES AND METHODS OF USE FOR RNA MAPPING
WO2021055833A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN110974954B (zh) 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
WO2021142306A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Variational autoencoder for biological sequence generation
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
MX2022009429A (es) 2020-01-30 2022-08-25 Modernatx Inc Composiciones para la inmunizacion contra virus respiratorios.
MX2022009410A (es) 2020-01-31 2022-10-18 Modernatx Inc Metodos de preparacion de nanoparticulas lipidicas.
IL295377A (en) 2020-02-07 2022-10-01 Modernatx Inc sars-cov-2 mRNA domain vaccines
CN114206827B (zh) 2020-04-09 2023-05-23 苏州艾博生物科技有限公司 脂质纳米颗粒组合物
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
KR20230015351A (ko) 2020-04-22 2023-01-31 화이자 인코포레이티드 코로나바이러스 백신
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
JP2023526284A (ja) 2020-05-15 2023-06-21 トランスレイト バイオ， インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子製剤
US20230142529A1 (en) 2020-05-15 2023-05-11 Modernatx, Inc. Rna formulations for high volume distribution
US20230190761A1 (en) 2020-05-21 2023-06-22 Modernatx, Inc. Methylene blue stabilized mrna compositions
AU2021283934A1 (en) 2020-06-05 2023-01-19 Modernatx, Inc. Bacterial strains for DNA production
US20230285310A1 (en) 2020-08-06 2023-09-14 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022067010A1 (en) 2020-09-25 2022-03-31 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
JP2023544197A (ja) 2020-10-06 2023-10-20 トランスレイト バイオ， インコーポレイテッド 脂質ナノ粒子の改善された方法および製剤
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
US20240041785A1 (en) 2020-11-16 2024-02-08 BioNTech SE Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20230000970A1 (en) 2021-01-11 2023-01-05 Modernatx, Inc. Seasonal rna influenza virus vaccines
AU2022208057A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
WO2022155530A1 (en) 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
EP4301405A1 (en) 2021-03-05 2024-01-10 ModernaTX, Inc. Vlp enteroviral vaccines
EP4313072A1 (en) 2021-03-26 2024-02-07 ModernaTX, Inc. Pertussis vaccine
EP4314000A1 (en) 2021-03-31 2024-02-07 ModernaTX, Inc. Synthesis of trinucleotide and tetranucleotide caps for mrna production
AU2022249357A1 (en) 2021-04-01 2023-10-12 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
JP2024515035A (ja) 2021-04-01 2024-04-04 モデルナティエックス インコーポレイテッド ｍＲＮＡによる抗体構造及びアイソタイプの粘膜発現
CN117529335A (zh) 2021-04-13 2024-02-06 摩登纳特斯有限公司 爱泼斯坦-巴尔病毒mrna疫苗
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
JP2024514182A (ja) 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド 呼吸器ウイルス組み合わせワクチン
JP2024513999A (ja) 2021-04-14 2024-03-27 モデルナティエックス インコーポレイテッド インフルエンザ－コロナウイルス組み合わせワクチン
WO2022232585A1 (en) 2021-04-29 2022-11-03 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4355761A1 (en) 2021-06-14 2024-04-24 ModernaTX, Inc. Mrna vaccines encoding flexible coronavirus spike proteins
WO2022266012A1 (en) 2021-06-14 2022-12-22 Modernatx, Inc. Coronavirus glycosylation variant vaccines
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
WO2023283642A2 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus concatemeric vaccines
WO2023283645A1 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus domain vaccines
WO2023283651A1 (en) 2021-07-09 2023-01-12 Modernatx, Inc. Pan-human coronavirus vaccines
WO2023014649A1 (en) 2021-08-02 2023-02-09 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
WO2023018773A1 (en) 2021-08-11 2023-02-16 Modernatx, Inc. Lipid nanoparticle formulations and methods of synthesis thereof
WO2023019181A1 (en) 2021-08-11 2023-02-16 Modernatx, Inc. Sars-cov-2 lipid nanoparticle vaccine formulations
TW202321446A (zh) 2021-08-13 2023-06-01 美商現代公司 多管柱層析ｍＲＮＡ純化
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023114307A1 (en) 2021-12-15 2023-06-22 Modernatx, Inc. Determination of encapsulation efficiency of lipid nanoparticles
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
WO2023150256A1 (en) 2022-02-03 2023-08-10 Modernatx, Inc. Continuous precipitation for mrna purification

Also Published As

Publication number Publication date
EP4349404A2 (en) 2024-04-10
EP3718565A1 (en) 2020-10-07
EP3364983A4 (en) 2019-10-23
US10064934B2 (en) 2018-09-04
US20200282046A1 (en) 2020-09-10
US10272150B2 (en) 2019-04-30
MA52645A (fr) 2021-03-24
US20170340725A1 (en) 2017-11-30
WO2017070626A3 (en) 2017-08-03
DK3718565T3 (da) 2022-06-20
EP4011451A1 (en) 2022-06-15
SI3718565T1 (sl) 2022-08-31
HUE059127T2 (hu) 2022-10-28
US20180326045A1 (en) 2018-11-15
TW201729835A (zh) 2017-09-01
DE20164728T1 (de) 2021-09-30
US20190216917A1 (en) 2019-07-18
US20190240317A1 (en) 2019-08-08
ES2922760T3 (es) 2022-09-20
EP3364983A2 (en) 2018-08-29
US10702600B1 (en) 2020-07-07
MA52645B1 (fr) 2022-06-30
WO2017070626A2 (en) 2017-04-27
EP4349405A2 (en) 2024-04-10
US11872278B2 (en) 2024-01-16
MD3718565T2 (ro) 2022-09-30
US10702599B2 (en) 2020-07-07
EP3718565B1 (en) 2022-04-27
MA47016A (fr) 2018-08-29
RS63381B1 (sr) 2022-08-31
US20200197510A1 (en) 2020-06-25
HRP20220872T1 (hr) 2022-12-23
LT3718565T (lt) 2022-06-10
US10543269B2 (en) 2020-01-28
US10933127B2 (en) 2021-03-02
PT3718565T (pt) 2022-07-20
US20200405844A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
HUE059127T2 (hu) Légúti vírusok elleni vakcinák
IL258831A (en) Assemble respiratory syncytial virus
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
HK1256169A1 (zh) 傳染病疫苗
LT3393510T (lt) Zikos viruso vakcina
HK1246183A1 (zh) Hpv疫苗
SG10201913630YA (en) Zika virus vaccine
ZA201700165B (en) Influenza virus vaccines and uses thereof
GB201518684D0 (en) Vaccine
GB201406608D0 (en) Virus
SG11201610443WA (en) Influenza virus vaccines and uses thereof
GB201613191D0 (en) Zika virus vaccine
GB201522132D0 (en) Vaccine
GB201419572D0 (en) Virus
GB201506041D0 (en) Avian vaccine
LT3383428T (lt) Respiracinio sincitinio viruso vakcina
IL249704A0 (en) Influenza virus vaccines and their uses
IL249705A0 (en) Influenza virus vaccines and their uses
PT3393510T (pt) Vacina contra o vírus zika
GB201522013D0 (en) Virus
GB201516936D0 (en) Virus
GB201507419D0 (en) Virus
GB201507529D0 (en) Virus preparations
GB201408046D0 (en) Virus preparations
GB201406470D0 (en) Virus